Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

We have 14 Toxicology (drug development) PhD Projects, Programmes & Scholarships

Discipline

Discipline

Medicine

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


Toxicology (drug development) PhD Projects, Programmes & Scholarships

We have 14 Toxicology (drug development) PhD Projects, Programmes & Scholarships

Endosomal Sorting Complex Required for Transport (ESCRT): Investigation of the role in acquired drug resistance in colon cancer

  Research Group: Institute of Cancer Therapeutics
Despite treatment advances, one of the most common cancers, colorectal cancer (CRC), still has a 45% mortality rate, and one of the major problems is the build-up of resistance to cancer drugs during treatment (‘acquired resistance’) such that over time the drugs stop working. Read more

Drug metabolism - prediction, detection, and isolation

Electrosynthesis (ES) is a green methodology for preparing and interpreting drug metabolites linked to toxicology. ES describes the synthesis of chemical compounds in an electrochemical cell. Read more

Crystal engineering new, more effective medicines.

RESEARCH PROJECT. To uncover pharmaceutical problems, our team collaborates with a wide range of disciplines, including pharmacists, pharmaceutical scientists, chemists and engineers at internationally renowned pharmacy departments and at multinational pharmaceutical companies. Read more

Design, synthesis and evaluation of novel polysialyltransferase inhibitors as anti- metastatic agents

  Research Group: Institute of Cancer Therapeutics
Polysialic acid plays an essential role in neuronal development, but by adulthood is absent from the human body. Its biosynthesis is regulated by two polysialyltransferases (polySTs). Read more

Development of a personalized therapy for pulmonary arterial hypertension (PAH)

  Research Group: Pharmacology and Experimental Therapeutics
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death. Read more

Discovery and profiling of small-molecule inhibitors of cellular nuclease enzymes

Nuclease enzymes are non-traditional drug targets that attract an increasing amount of interest as potential targets relevant for a variety of therapeutic areas including infection, cancer and bone disease. Read more

Polysialyltransferases as a target in metastatic cancer

  Research Group: Institute of Cancer Therapeutics
Polysialic acid plays an essential role in neuronal development, but by adulthood is absent from the human body. Its biosynthesis is regulated by two polysialyltransferases. Read more

Personalising cancer treatment with tumour evolution modelling using AI-based genomics biomarkers and PK/PD

Tumour heterogeneity is a major problem limiting the efficacy of targeted oncological therapies. Most advanced tumours eventually become resistant to the treatments, ultimately making the patient succumb to metastatic disease. Read more

Network-based predictive modelling of cardiovascular disease risk

The risk of cardiovascular disease (CVD) is orchestrated by multiple factors. QRISK models (currently QRISK3) have been used in the UK to estimate CVD risk within the next 10 years for individuals without CVD. Read more
  • 1

Filtering Results